All In Biotech

Drug Trial Radar · NCT05875168

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Aug 18, 2023

Primary completion

Aug 11, 2028

Study completion Nov 11, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • DS-3939aDrug

    One IV infusion Q3W on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939aTime frame: Approximately 3 months after first dosing
  2. Overall Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events Following Treatment With DS-3939aTime frame: Up to approximately 31 months
  3. Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 2)Time frame: Up to approximately 31 months
  4. PSA50 Response Rate Following Treatment with DS-3939a (Part 2; CRPC only)Time frame: Up to approximately 31 months

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida · Withdrawn

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Piedmont Cancer Institute

    Locust Grove, Georgia · Withdrawn

  • University of Kansas Medical Center

    Westwood, Kansas · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Withdrawn

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Icahn School of Medicine Mt Sinai

    New York, New York · Withdrawn

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Withdrawn

  • The Medical College of Wisconsin, INC

    Milwaukee, Wisconsin · Recruiting

  • The Medical College of Wisconsin, INC

    Milwaukee, Wisconsin · Withdrawn

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • McGill University Health Center

    Montreal, Canada · Withdrawn

  • Princess Margaret Cancer Center

    Toronto, Canada · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Withdrawn

  • Jilin Cancer Hospital

    Changchun, China · Withdrawn

  • Hunan Cancer Hospital

    Changsha, China · Withdrawn

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Second Peoples Hospital of Neijiang

    Neijiang, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Withdrawn

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Withdrawn

  • The First Affiliated Hospital of Xiâan Jiaotong University

    Xi'an, China · Withdrawn

  • Xiangyang Central Hospital

    Xiangyang, China · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Withdrawn

  • Assistance Publique- de Marseille

    Marseille, France · Recruiting

  • Ico - Site René Gauducheau

    Saint-Herblain, France · Recruiting

  • Chu Strasbourg

    Strasbourg, France · Withdrawn

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • National Cancer Center Hospital

    Chūōku, Japan · Recruiting

  • Kansai Medical University Hospital

    Hirakata-shi, Japan · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.